Clinical trial
Study Evaluating AGG-523 in Subjects With Osteoarthritis
NCT00427687 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00427687 |
|---|---|
| Title | Study Evaluating AGG-523 in Subjects With Osteoarthritis |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | AGG-523 |
| Start date | Feb 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jan 29, 2007 |
| Last update posted | Aug 5, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: